ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "pregnancy"

  • Abstract Number: 2425 • ACR Convergence 2023

    Pregnancy Outcomes Among Patients with Vasculitis Using Administrative Claims Data

    Amadeia Rector1, Julia Simard2, Gary Shaw3 and Audra Horomanski4, 1Stanford University, San Francisco, CA, 2Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, 3Stanford University, Stanford, CA, 4Stanford University, Palo Alto, CA

    Background/Purpose: Systemic vasculitides are rare, heterogeneous, inflammatory disorders associated with high morbidity and mortality. Recent management and therapeutic advances have improved life expectancy and reproductive…
  • Abstract Number: 0103 • ACR Convergence 2023

    Criteria and Non-criteria Antiphospholipid Autoantibodies Screening in Women with Unexplained Fetal Death, Pre-eclampsia And/or Fetal Growth Restriction: A Cross-sectional Study

    Tiphaine Goulenok1, Clothilde Gros1, Arthur Mageau2, Tiphaine Barral1, Pascale Roland Nicaise1, Marie Helene Saint Frison1, Margot Bucau1, Valerie Vivier1, Valentine Marie Ferre2, Agnes Bourgeois Moine1, Thomas Papo2 and Karim Sacre2, 1Assistance Publique Hopitaux de Paris, Paris, France, 2Université Paris Cité, Paris, France

    Background/Purpose: Antiphospholipid syndrome (APS) is a cause of pregnancy morbidity. Late pregnancy morbidity occurs in up to 25% of pregnant women with APS and may…
  • Abstract Number: 0478 • ACR Convergence 2023

    The Long-term Neurodevelopmental Outcome of Children Born to Women with Systemic Sclerosis: Assessment Through a Self-reported Questionnaire by the Mothers and Nneuropsychiatric Evaluations of the Children

    Maria Grazia Lazzaroni1, Eleonora Pedretti1, Liala Moschetti1, Marzia Bendoni2, Lucrezia Visconti2, Anna Molinaro2, Cecilia Nalli3, Franco Franceschini3, Paolo Airò1, Jessica Galli2, Elisa Fazzi2, Angela Tincani4 and Laura Andreoli5, 1Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy, 2Unit of Child and Adolescent Neuropsychiatry, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy, 3Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, 4Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, University of Brescia, Gussago, Italy, 5University of Brescia, Brescia, Italy

    Background/Purpose: The long-term neuropsychiatric (NP) outcome of children born to mothers affected by autoimmune diseases (AIDs) represents a controversial topic, with few studies1-3 reporting a…
  • Abstract Number: 1357 • ACR Convergence 2023

    Systemic Lupus Erythematosus and Assisted Reproductive Technology: A Case Series and Systematic Literature Review

    Erinn Coe1, Emily Petrinec1 and Omer Pamuk2, 1Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH, 2Division of Rheumatology, Case Western Reserve University/University Hospitals, Cleveland, OH

    Background/Purpose: Systemic lupus erythematosus (SLE) is one of the most common autoimmune diseases in women of childbearing age and female sex hormones are known to…
  • Abstract Number: 2481 • ACR Convergence 2023

    Pre-pregnancy Gene Expression Signatures Among Women with Rheumatoid Arthritis May Represent Predictive Biomarkers for Subsequent Improvement or Worsening During Pregnancy

    Matthew Wright1, Mette Smed2, Lee Nelson3, Jørn Olsen4, Merete Hetland5, Nicholas Jewell6, Vibeke Zoffmann2 and Damini Jawaheer1, 1Northwestern University, Chicago, IL, 2Juliane Marie Centre, Rigshospitalet, Copenhagen, Denmark, 3Fred Hutchinson Cancer Center, Seattle, WA, 4Aarhus University Hospital, Aarhus, Denmark, 5Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, 6London School of Hygiene and Tropical Medicine, London, United Kingdom

    Background/Purpose: Rheumatoid arthritis (RA) can improve naturally during pregnancy in a substantial proportion of women (50-75%), while it may worsen or remain unchanged in others.…
  • Abstract Number: 0104 • ACR Convergence 2023

    Cluster Analysis of Antiphospholipid Antibodies Associated Adverse Pregnancy Outcome Patients: Based on a 13-year Longitudinal Cohort Study

    Yin Long1, Jiuliang zhao2, Mengtao Li2, Xinping Tian2 and xiaofeng Zeng3, 1Peking Union Medical College Hospital Department of Rheumatology and Clinical Immunology, Beijing, China, 2Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 3Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    Background/Purpose: Antiphospholipid antibodies (aPLs) play a pivotal role in the etiology of adverse pregnancy outcomes (APOs). (1) Women with persistently aPLs positivity present heterogeneous clinical…
  • Abstract Number: 0479 • ACR Convergence 2023

    Exploring Reproductive Experiences with Women Enrolled in the Vasculitis Pregnancy Registry

    Catherine Sims1, Christine Yeung2, Heather Tam3, Joyce Kullman4, Amanda Eudy5, Renee Borchin6, Cristina Burroughs6, Megan Clowse7 and Peter Merkel2, 1Duke University School of Medicine, Durham, NC, 2University of Pennsylvania, Philadelphia, PA, 3Vasculitis Patient Powered Research Network, Stanford, CA, 4Vasculitis Foundation, Kansas City, MO, 5Duke University, Raleigh, NC, 6University of South Florida, Tampa, FL, 7Duke University, Chapel Hill, NC

    Background/Purpose: There are limited data on the reproductive health and experiences of women with vasculitis. This study engaged women with vasculitis to understand their perspectives…
  • Abstract Number: 1360 • ACR Convergence 2023

    Factors Associated with Medication-related Concerns in Women with Inflammatory Rheumatic Diseases – an Analysis of a Nationwide Pregnancy Cohort

    Yvette Meissner1, Bernhard Eickhoff1, Cornelia Glaser2, Joerg Henes3, Jutta Richter4, Susanna Spaethling-Mestekemper5, Christof Specker6, Rebecca Fischer-Betz4 and Anja Strangfeld1, 1German Rheumatism Research Center, Berlin, Germany, 2Department of Rheumatology and Clinical Immunology University Medical Center Freiburg, Freiburg, Germany, 3University Hospital Tuebingen, Tuebingen, Germany, 4Clinic for Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Düsseldorf, Germany, 5Rheumapraxis Muenchen, Muenchen, Germany, 6Department of Rheumatology and Clinical Immunology, Kliniken Essen-Mitte, Essen, Germany

    Background/Purpose: Pregnancies in women with chronic diseases are often accompanied by concerns about potential complications [1]. This analysis explored medication-related concerns among women with inflammatory…
  • Abstract Number: 0110 • ACR Convergence 2023

    Neutrophil Extracellular Traps as Mediators of Antiphospholipid Antibody-Induced Trophoblast Dysfunction and Fetal Loss

    Christine Rysenga, Srilakshmi Yalavarthi, Wenying Liang, Claire Hoy, Cyrus Sarosh, Richard Lieberman, Yu Zuo and Jason Knight, University of Michigan, Ann Arbor, MI

    Background/Purpose: Antiphospholipid antibodies (aPL) induce obstetric complications associated with placental insufficiency by promoting trophoblast dysfunction and inflammation at the maternal-fetal interface. Neutrophils have been found…
  • Abstract Number: 0586 • ACR Convergence 2023

    Therapeutic Drug Monitoring of Azathioprine and Tacrolimus in SLE Pregnancies: Preliminary Results from the LEGACY Cohort

    Reem Farhat1, Arielle Mendel2, Isabelle Malhamé3, Joo Young (Esther) Lee4, Luisa Ciofani5, Sasha Bernatsky6 and Evelyne Vinet2, 1McGill University, Montréal, QC, Canada, 2McGill University Health Centre, Montréal, QC, Canada, 3McGill University Health Centre, Montreal, QC, Canada, 4McGill University, Montreal, QC, Canada, 5McGill University Health Center, Montreal, QC, Canada, 6Research Institute of the McGill University Health Centre, Montreal, QC, Canada

    Background/Purpose: Pregnant SLE women still face an unacceptably high risk of maternal and fetal morbidity, particularly when their disease is active. How to personalize SLE…
  • Abstract Number: 1361 • ACR Convergence 2023

    Effect of Zen/Doria Remission and Glucocorticoid Dosage on the Pregnancy Outcome of SLE: Retrospective Study in Two Japanese Tertiary Referral Centers

    Takehiro Nakai1, Nanase Honda2, Sho Fukui3, Ayako Kitada1, Naoto Yokogawa4 and Masato Okada1, 1St. Luke's International Hospital, Tokyo, Japan, 2Tokyo Metropolitan Tama Medical Center, Fuchu-shi, Japan, 3Brigham and Women's Hospital, Boston, MA, 4Tokyo Metropolitan Tama Medical Center, Taito City, Tokyo, Japan

    Background/Purpose: Achieving remission is one of the treatment targets in the lupus care and it is also important in preventing the prevalence of adverse pregnancy…
  • Abstract Number: L13 • ACR Convergence 2022

    Fetal Cardiac Targets Identify the Autoantibodies Associated with Congenital Heart Block

    Stephanie Benjamin1, Lisa Vi2, Diptendu Chatterjee1, Edgar Jaeggi1, Marie Wahren-Herlenius3, Amelia Ruffatti4, Linda Hiraki5, Michelle Lohbihler2, Lusia Sepiashvili1, Carl Laskin6, Meena Fatah1, Daniela Dominguez5, Lawrence Ng5, Anthony Gramolini2, Vincent Christoffels7, Stephanie Protze2 and Robert Hamilton8, 1Hospital for Sick Children, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, 4Universitå di Padova, Padova, Italy, 5The Hospital for Sick Children, Toronto, ON, Canada, 6Mt. Sinai Hospital/University of Toronto, Toronto, ON, Canada, 7Amsterdam UMC, Amsterdam, Zuid-Holland, Netherlands, 8Hospital for Sick Children, Markham, ON, Canada

    Background/Purpose: Autoimmune congenital heart block (CHB+) affects the fetus of mothers with anti-Ro antibodies. Anti-Ro (Ro+) antibodies (Abs) are usually present in maternal sera when…
  • Abstract Number: 0950 • ACR Convergence 2022

    Obstetric Outcomes in Women with Rheumatic Disease and COVID-19 in the Context of Vaccination Status: Data from the COVID-19 Global Rheumatology Alliance Registry

    Sinead Maguire1, Samar Al emadi2, Paul Alba3, Mathia C Aguiar4, Talal Al Lawati5, Gelsomina Alle6, Bonnie Bermas7, Suleman Bhana8, Branimir Anic9, Inita Bulina10, Megan Clowse11, Adriana Karina Cogo12, Iris Colunga13, Claire Cook14, KAREN JOYCE CORTEZ15, Kathryn Dao16, Milena Gianfrancesco17, Monique Gore-Massy18, Laure Gossec19, Rebecca Grainger20, Jonathan Hausmann21, Tiffany YT Hsu22, Kimme Hyrich23, Carolina Isnardi24, Yumeko Kawano22, Rachael Kilding25, Daria A Kusevich26, Saskia Lawson-Tovey27, Jean Liew28, Eoghan McCarthy29, Anna Montgomery30, Sebastian Moyano3, Noreen Nasir31, IVAN PADJEN32, Charalampos Papagoras33, Naomi Patel34, MARIANA PERA35, Cecilia Pisoni36, Guillermo Pons-Estel37, Antonio Lorenzo Quiambao38, Rosana Quintana39, Eric Ruderman40, Sebastian Sattui41, Veronica Savio42, Savino Sciascia43, Marieta Sencarova44, Rosa Serrano-Morales45, Faizah Siddique46, Emily Sirotich47, Jeffrey Sparks48, Anja Strangfeld49, Paul Sufka50, Helen Tanner51, Yohana Tissera52, Zachary Wallace14, Marina Werner53, Leanna Wise54, Angus Worthing55, JoAnn Zell56, Julija Zepa10, Pedro Machado57, Jinoos Yazdany17, Philip Robinson51 and Richard Conway1,1St James' Hospital, Dublin, Ireland, 2Hamad Medical Corporation, Doha, Qatar, 3Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 4Hospital General Agustin O`Horan, Merida, Mexico, 5Sultan Qaboos University Hospital, Muscat, Oman, 6Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 7UT Southwestern, Dallas, TX, 8Crystal Run Healthcare, Middletown, NY, 9Clinical Hospital Centre Zagreb, School of Medicine, University of Zagreb, Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Zagreb, Croatia, 10Center of Rheumatology, Paul Stradins Clinical University hospital, Riga, Latvia, 11Duke University, Durham, NC, 12Hospital Interzonal Luis Guemes, Haedo and Hospital San Juan de Dios, Castelar, Buenos Aires, Argentina, 13Hospital Universitario UANL, Monterrey, Mexico, 14Massachusetts General Hospital, Boston, MA, 15Baguio General Hospital Medical Center, Baguio, Philippines, 16UT Southwestern Medical Center, Dallas, TX, 17University of California San Francisco, San Francisco, CA, 18Covid-19 GRA, West Orange, NJ, 19Sorbonne Université, Paris, France, 20University of Otago, Wellington, New Zealand, 21Division of Immunology, Boston Children's Hospital, Boston, MA, 22Brigham and Women's Hospital, Boston, MA, 23The University of Manchester, Manchester, United Kingdom, 24SAR-COVID Coordinator, Research Unit Argentine Society of Rheumatology, Buenos Aires, Argentina, 25Sheffield teaching hospitals trust, Sheffield, United Kingdom, 26VA Nasonova Research Institute of Rheumatology, Moscow and Anikina Clinic, Vidnoe, Russia, 27Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, the University of Manchester, Manchester, UK AND National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, 28Boston University, Boston, MA, 29Beaumont Hospital, Dublin, Ireland, 30University of California, San Francisco, USA; San Francisco VA Medical Center, San Francisco, USA, San Francisco, CA, 31Aga Khan University Hospital, Karachi Pakistan, Karachi, Pakistan, 32University Hospital Center Zagreb, Zagreb, Croatia, 33First Department of Internal Medicine and Laboratory of Molecular Hematology, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece, 34Massachusetts General Hospital, Sale Creek, TN, 35Hospital Ángel C Padilla, San Miguel de Tucumán, Tucuman, Argentina, 36CEMIC- Centro de Educación Médica e Investigaciones Clínicas, Buenos Aires, Argentina, 37Argentine Society of Rheumatology, Buenos Aires, Argentina, 38East Avenue Medical Center, Quezon City, Philippines, 39Centro Regional de Enfermedades Autoinmunes y Reumáticas. Grupo Oroño (GO CREAR) and Research Unit Argentine Society of Rheumatology, Buenos Aires, Argentina, 40Northwestern University Feinberg School of Medicine, Chicago, IL, 41University of Pittsburg, Pittsburg, Pennsylvania, USA, PIttsburgh, PA, 42Hospital Córdoba; Consultora Integral de Salud CMP, Cordoba, Argentina, 43University of Turin, Torino, Italy, 44Univerzitna nemocnica L Pasteura, Slovakia, Kosice, Slovakia, 45Sanatorio Parque. Centro de Enfermedades Autoinmunes y Reumáticas del Grupo Oroño, Rosario, Argentina, 46Loyola University Medical Center, Elmhurst, IL, 47Department of Health Research, Evidence and Impact, McMaster University, Hamilton, ON, Canada, 48Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 49Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, 50HealthPartners, Eagan, MN,51University of Queensland School of Medicine, Brisbane, Queensland, Australia, 52Internal Medicine Service, Rheumatology Unit, Hospital Córdoba y Sanatorio Parque de Córdoba, Córdoba, Argentina, 53Hospital Nacional de Clínicas, Córdoba, Argentina, 54LAC+USC/Keck Medicine of USC, Pasadena, CA, 55Arthritis & Rheumatism Associates, PC, Washington, DC, 56University of Colorado Anschutz Medical Campus, Aurora, CO, 57Centre for Rheumatology & Department of Neuromuscular Diseases, University College London and National Institute for Health Research (NIHR), University College London Hospitals NHS Foundation Trust, and Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, London, United Kingdom

    Background/Purpose: To describe obstetric outcomes based on COVID-19 vaccination status in women with rheumatic and musculoskeletal diseases (RMDs) who developed COVID-19 during pregnancy.Methods: We extracted…
  • Abstract Number: 0969 • ACR Convergence 2022

    Use of Gonadotropin-releasing Hormone Agonists for Ovarian Preservation in Patients Receiving Cyclophosphamide for Systemic Lupus Erythematosus: A Meta-analysis

    Komal Ejaz1, Dania Abid2, Paul Juneau3, Jun Chu4 and Sarfaraz Hasni5, 1The Wright Center for Graduate Medical Education, Scranton, PA, 2Idaho College of Osteopathic Medicine, Meridian, ID, 3National Institutes of Health Library, Bethesda, MD, 4National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 5National Institutes of Health, Bethesda, MD

    Background/Purpose: Cyclophosphamide (CYC) has known cytotoxic effects on ovarian reserve and has been linked to premature ovarian failure in systemic lupus erythematosus (SLE). The concurrent…
  • Abstract Number: 0952 • ACR Convergence 2022

    Pregnancy Course and Outcomes of Patients with Polymyositis and Dermatomyositis (PM/DM) in Our Institution

    Rina Mino1, Hiromi Shimada2, Risa Wakiya2, shusaku nakashima3, Mikiya Kato2, taichi miyagi4, Yusuke Ushio5, Kanako Chujo6, Tomohiro Kameda2 and Hiroaki Dobashi7, 1Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Miki-cho, Kita-gun, Japan, 2Kagawa University, Kagawa, Japan, 3Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, 4Kagawa University, Kidagun, Japan, 5Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki, Kita District, Kagawa, Japan, 6Kagawa University, Miki, Kita District, Kagawa, Japan, 7Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Kagawa, Japan

    Background/Purpose: The purpose of this study is to determine the association between changes in disease activity during pregnancy and pregnancy outcome by analyzing a case…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 19
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology